IP Verse

Revance Therapeutics competitive analysis

Latest publications and patents of Revance Therapeutics New

Explore the latest publications and patents granted to Revance Therapeutics, showcasing their recent innovations and technological advancements.

Last updated on: Sep 23, 2025

Publication Number	Publication Date	Title	Legal Status
Get instant update for new patents of Revance Therapeutics
EP2490986	Apr 24, 2024	Methods And Systems For Purifying Non-Complexed Botulinum Neurotoxin	Patent Maintained As Amended
EP3368071	Jan 26, 2022	Injectable Botulinum Toxin Formulations And Methods Of Use Thereof Having Long Duration Of Therapeutic Or Cosmetic Effect	Granted And Under Opposition
EP2661276	Aug 2, 2017	Methods And Kits For Topical Application, Removal, And Inactivation Of Therapeutic Or Cosmetic Toxin Compositions	Revoked

Latest patents of Revance Therapeutics opposed by its competitors

Explore Revance Therapeutics's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Sep 25, 2025

Patent Number	Grant Date	Title	Total Oppositions
EP2490986	Apr 24, 2024	Methods And Systems For Purifying Non-Complexed Botulinum Neurotoxin	1
EP3368071	Jan 26, 2022	Injectable Botulinum Toxin Formulations And Methods Of Use Thereof Having Long Duration Of Therapeutic Or Cosmetic Effect	1
EP2661276	Aug 2, 2017	Methods And Kits For Topical Application, Removal, And Inactivation Of Therapeutic Or Cosmetic Toxin Compositions	1

Latest PTAB cases involving Revance Therapeutics

Discover the latest PTAB cases involving Revance Therapeutics, highlighting their recent legal challenges and patent disputes.

Last updated on: Sep 29, 2025

Proceeding Number	Filing Date	Petitioner	Respondent	Status
Get alerts for PTAB Cases involving Revance Therapeutics
IPR2021-01204	Jul 1, 2021	REVANCE THERAPEUTICS	MEDY TOX	Institution Denied
IPR2021-01203	Jul 1, 2021	REVANCE THERAPEUTICS	MEDY TOX	Institution Denied

Peer Comparison New

IP litigation analysis comparing Revance Therapeutics with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Sep 25, 2025

Company	Oppositions Filed	Oppositions Faced	PTAB Cases Filed	PTAB Cases Faced	Strategy Type
REVANCE THERAPEUTICS	-	3	2	-	Balanced
ALLERGAN	11	28	13	33	Balanced
IPSEN BIOPHARMA	2	-	-	-	Highly Aggressive
MEDY TOX	-	2	-	3	Non-Active